In this article we are going to list the 10 biggest pharmaceutical companies in the world. For a detailed coverage of this topic and a more comprehensive list please take a look at the 25 biggest pharmaceutical companies in the world.
10. Novo Nordisk A/S (NYSE:NVO)
Total market cap as at 26 Feb 2023 (in billions): $322.1
Total TTM revenue of the company (in billions): $25.1
Novo Nordisk A/S (NYSE:NVO) recently celebrated crossing the $300 million market cap, and is still continuing to improve, making it the second most valuable pharma company in the world.
9. AstraZeneca PLC (NASDAQ:AZN)
Total market cap as at 26 Feb 2023 (in billions): $209.3
Total TTM revenue of the company (in billions): $44.4
AstraZeneca PLC (NASDAQ:AZN) has entered the oncology space head on, which we mentioned as the area with the highest growth potential in pharma. In the last one year, AstraZeneca PLC (NASDAQ:AZN) has spent around $90 million on antibody drug conjugates.
8. Eli Lilly and Company (NYSE:LLY)
Total market cap as at 26 Feb 2023 (in billions): $305.7
Total TTM revenue of the company (in billions): $28.5
American pharmaceutical companies dominate the list of the biggest pharmaceutical companies in the world and the trend continues with Eli Lilly and Company (NYSE:LLY), with its obesity drug Mounjaro finally back on shelf after two months due to unprecedented demand.
7. Bayer
Total market cap as at 26 Feb 2023 (in billions): $58.6
Total TTM revenue of the company (in billions): $52.8
The largest Germany pharmaceutical company, according to Seeking Alpha, the company’s valuation could potentially double in the next 12-18 months. as its currently trading at historically low multiples.
6. Novartis AG (NYSE:NVS)
Total market cap as at 26 Feb 2023 (in billions): $183.2
Total TTM revenue of the company (in billions): $51.8
Novartis AG (NYSE:NVS) is a Swiss pharma company which currently has over 100,000 employees. Currently, Novartis AG (NYSE:NVS) is engaged in portfolio optimization and one of its research projects that the company has shed is nonalcoholic steatohepatitis (NASH).
5. AbbVie Inc. (NYSE:ABBV)
Total market cap as at 26 Feb 2023 (in billions): $270.2
Total TTM revenue of the company (in billions): $58.1
AbbVie Inc. (NYSE:ABBV), a spin-off of Abbott Laboratories, was only established 10 years ago but is competing head to head with long established pharma giants.
4. Roche Group
Total market cap as at 26 Feb 2023 (in billions): $238.0
Total TTM revenue of the company (in billions): $68.5
The Swiss pharmaceutical giant, the biggest such company in Europe, spent around $1 billion for cancer drug Gavreto. After significant underperformance, Roche terminated the collaboration with Blueprint Medicines, producers of the drug.
3. Merck & Co., Inc. (NYSE:MRK)
Total market cap as at 26 Feb 2023 (in billions): $278.6
Total TTM revenue of the company (in billions): $59.3
Merck & Co., Inc. (NYSE:MRK) was once the American arm of Germany’s Merck group, a company over 350 years old but is now an independent company and one of the largest pharmaceutical companies in the world. Merck & Co., Inc. (NYSE:MRK) has recently faced an issue in its European markets as the EU regulator has recommended against giving approval for its Covid pill for adults.
2. Pfizer Inc. (NYSE:PFE)
Total market cap as at 26 Feb 2023 (in billions): $234.4
Total TTM revenue of the company (in billions): $100.3
Pfizer Inc. (NYSE:PFE) has made an important breakthrough recently with its RSV vaccine, but according to the FDA, a rare neurological condition is considered to be “an important potential risk” of the vaccine, with two people being diagnosed with the condition in a clinical trial.
1. Johnson & Johnson (NYSE:JNJ)
Total market cap as at 26 Feb 2023 (in billions): $406.2
Total TTM revenue of the company (in billions): $94.9
Easily topping the list of the 25 biggest pharmaceutical companies in the world is Johnson & Johnson (NYSE:JNJ), one of the few companies to come up with a viable Covid-19 vaccine. In addition, it is also among the most profitable companies in the world Johnson & Johnson (NYSE:JNJ) has attempted to divide its company in two businesses, assigning the more than 40,000 cancer claims against its products, and then claiming bankruptcy. Unfortunately for Johnson & Johnson (NYSE:JNJ), this tactic has been unsuccessful, with a U.S. court ruling that only companies who are facing financial stress can file for bankruptcy.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on 10 High Growth Micro-cap Stocks to Buy and 12 High Growth Penny Stocks that are Profitable.
